title: Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer.
abstract: Breast cancers frequently have osteoclastic bone metastases that are difficult to monitor and treat. Bone scintigraphy with 99mTc-labeled biphosphonates is still the reference method for detecting and localizing bone involvement. Classical biochemical markers such as urinary calcium have poor sensitivity for detecting and monitoring metastases of breast cancers. New biochemical markers for the study of bone remodeling have recently been developed, including a degradation product of the C-terminal end of the telopeptide of type I collagen (CTX). We used an immunoenzymatic assay technique for urinary CTX in 84 pre- and post-menopausal women and demonstrated a correlation between scintigraphic scores and urinary CTX concentrations. CTX values are significantly different between the control group and patients with bone metastasis, except those with score 0. There is a regular increase in urinary CTX concentration from score 0 (no abnormal uptake) to score 4 (diffuse carcinomatosis). There is no significant variation between control population and score 0 to 3 for urinary calcium. Only women with scintigraphic score 4 have significantly increased urinary calcium concentrations. Measuring CTX in pre- and post-menopausal patients during breast cancer chemotherapy might be of great interest for monitoring the development of metastases and the therapeutic efficacy of chemotherapy.
authors.affiliation: Laboratoire de Biochimie, Hôpital St Louis, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Houzé
authors.forename: B
authors.initials: B
authors.lastname: Bellik
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: F
authors.initials: F
authors.lastname: Bouro
authors.forename: B
authors.initials: B
authors.lastname: Bousquet
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000652:urine*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D002118:Calcium / Q000652:urine; D003094:Collagen / Q000737:chemistry / Q000652:urine*; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010446:Peptide Fragments / Q000652:urine*; D017698:Postmenopause; D017697:Premenopause; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D003094:Collagen; D003404:Creatinine; D002118:Calcium